AnaptysBio (ANAB) Stock Price, News & Analysis

Company Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders. Among its leading candidates is ANB020, an anti-IL-33 antibody being evaluated for atopic dermatitis and eosinophilic asthma, and ANB019, an anti-IL-36 receptor antibody in development for generalized pustular psoriasis. In addition to its clinical assets, AnaptysBio is advancing several preclinical programs aimed at novel immuno-oncology targets, reflecting its commitment to broadening the therapeutic potential of its platform.

AnaptysBio has established strategic partnerships to enhance its research and development efforts. These collaborations include agreements with major pharmaceutical companies to co-develop and commercialize select antibody candidates. Through these alliances, AnaptysBio gains access to expanded development expertise, global regulatory capabilities, and commercialization support, while retaining rights to key programs emerging from its discovery engine.

Since completing its initial public offering in 2016, AnaptysBio has grown its team and infrastructure to support both early-stage discovery and late-stage clinical development. The company is led by President and Chief Executive Officer Hamza Suria and maintains research operations in the United States. AnaptysBio’s mission is to deliver differentiated antibody therapeutics that address unmet medical needs in inflammatory diseases and cancer.

Key Stats

• Today's Range: $68.39 to $72.36
• 50-Day Range: $50.95 to $70.22
• 52-Week Range: $11.40 to $72.36
• Volume: 472,599 shs
• Average Volume: 665,241 shs
• Market Capitalization: $2.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $76.18
• Consensus Rating: Moderate Buy

AnaptysBio Stock Analysis - MarketRank™

AnaptysBio scored higher than 43% of companies evaluated by MarketBeat, and ranked 567th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 10 buy ratings, 1 hold rating, and 1 sell rating.

Upside/Downside

The consensus price target for AnaptysBio is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

AnaptysBio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AnaptysBio are expected to grow in the coming year, from ($3.15) to ($1.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AnaptysBio is -133.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AnaptysBio is -133.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AnaptysBio has a P/B Ratio of 51.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

21.48% of the float of AnaptysBio has been sold short.

Short Interest Ratio / Days to Cover

AnaptysBio has a short interest ratio ("days to cover") of 7.97.

Change versus previous month

Short interest in AnaptysBio has recently decreased by 14.66%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AnaptysBio does not currently pay a dividend.

Dividend Growth

AnaptysBio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: -0.13

News Sentiment

AnaptysBio has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for AnaptysBio this week, compared to 6 articles on an average week.

Search Interest

7 people have searched for ANAB on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,787,594.00 in company stock.

Percentage Held by Insiders

33.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

AnaptysBio has minimal institutional ownership at this time.

ANAB Stock Analysis - Frequently Asked Questions

How have ANAB shares performed this year?

AnaptysBio's stock was trading at $48.48 at the beginning of 2026. Since then, ANAB stock has increased by 43.3% and is now trading at $69.4930.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings data on Tuesday, March, 3rd. The biotechnology company reported $1.58 EPS for the quarter, topping analysts' consensus estimates of $0.89 by $0.69. The biotechnology company had revenue of $108.25 million for the quarter, compared to the consensus estimate of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative trailing twelve-month return on equity of 1,101.24%.

Is AnaptysBio buying back stock?

AnaptysBio's board approved a share buyback plan on Friday, March 27th 2026, which authorizes the company to buy back $100,000,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 5,352,316.2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's board of directors believes its stock is undervalued.

When did AnaptysBio IPO?

AnaptysBio (ANAB) raised $75 million in an IPO on Thursday, January 26th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are AnaptysBio's major shareholders?

Top institutional shareholders of AnaptysBio include Hsbc Holdings PLC (0.43%), Bank of New York Mellon Corp (0.18%), Bleakley Financial Group LLC (0.15%) and SG Americas Securities LLC (0.09%). Insiders that own company stock include Ecor1 Capital, Llc, Daniel Faga, Paul F Lizzul, John P Schmid, Dennis Mulroy, Eric J Loumeau, Magda Marquet, J Anthony Ware, Hollings Renton and Dennis M Fenton.
View institutional ownership trends.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AnaptysBio investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Moderna (MRNA) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 3/03/2026
• Today: 5/06/2026
• H.C. Wainwright 2nd Annual Royalty Company Virtual Conference: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ANAB
• CIK: 1370053
• Web: www.anaptysbio.com
• Phone: (858) 362-6295
• Fax: N/A
• Employees: 100
• Year Founded: 2005

Price Target and Rating

• Average Price Target for AnaptysBio: $76.18
• High Price Target: $100.00
• Low Price Target: $50.00
• Potential Upside/Downside: +9.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.52)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.23 million
• Net Margins: -5.64%
• Pretax Margin: -5.57%
• Return on Equity: -1,101.24%
• Return on Assets: -3.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.07
• Quick Ratio: 9.07

Sales & Book Value

• Annual Sales: $234.60 million
• Price / Sales: 8.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.34 per share
• Price / Book: 51.86

Miscellaneous

• Outstanding Shares: 29,100,000
• Free Float: 19,352,000
• Market Cap: $2.02 billion
• Optionable: Optionable
• Beta: 0.79